Last week, Alexion disclosed in a filing to the US Securities and Exchange Commission that the European Patent Office did not grant Alexion its request for 2 patents on its brand-name eculizumab product, Soliris, a C5 complement inhibitor that treats rare and ultrarare diseases.
Last week, Alexion disclosed in a filing to the US Securities and Exchange Commission that the European Patent Office (EPO) did not grant Alexion its request for 2 patents on its brand-name eculizumab product, Soliris, a C5 complement inhibitor that treats rare and ultrarare diseases.
The Form 8-K, dated September 5, indicates that the office declined to grant patent application 3124029, which covers a pharmaceutical composition comprising an antibody or antibody fragment binding to C5 for use in treating a patient with paroxysmal nocturnal hemoglobinuria (PNH), and patent application 3167888, which relates to the composition of matter of eculizumab.
Alexion says that it is evaluating its options with respect to appealing the decision on these patents once it receives the office’s written decision.
The setback comes after the EPO revoked another patent for the drug, 2359834, following a multiparty opposition proceeding earlier this year. That patent had covered a pharmaceutical composition comprising a single-unit dosage form of an anti-C5 antibody or antibody fragment. Alexion signaled that it would appeal in that matter as well, and noted that, while an appeal is pending, the claims in the patent remain enforceable.
On the US front, Alexion faces challenges from Amgen, which recently saw the Patent Trial and Appeal Board institute 3 inter partes review proceedings for patents on eculizumab. The first is related to a method of treatment related to paroxysmal nocturnal hemoglobinuria by complement inhibition, the second concerns formulation, and the third is related to composition of matter.
Meanwhile, Amgen forges ahead with its development of its proposed biosimilar, ABP 959. The biosimilar developer is recruiting patients for a randomized, double-blind, phase 3 study of the proposed biosimilar in patients with PNH. Amgen expects to enroll 40 participants in this crossover assignment study that is expected to be completed in 2021.
Alexion also faces challenges from Samsung Bioepis, which has also begun enrolling patients in a phase 3 clinical trial of its proposed biosimilar—SB12—in PNH. Samsung Bioepis also expects its trial to be completed in 2021.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.